Selective Expression in Carotid Body Type I Cells of a Single Splice Variant of the Large Conductance Calcium- and Voltage-activated Potassium Channel Confers Regulation by AMP-activated Protein Kinase by Ross, Fiona A. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selective Expression in Carotid Body Type I Cells of a Single
Splice Variant of the Large Conductance Calcium- and Voltage-
activated Potassium Channel Confers Regulation by AMP-
activated Protein Kinase
Citation for published version:
Ross, FA, Rafferty, JN, Dallas, ML, Ogunbayo, O, Ikematsu, N, McClafferty, H, Tian, L, Widmer, H, Rowe,
ICM, Wyatt, CN, Shipston, MJ, Peers, C, Hardie, DG & Evans, AM 2011, 'Selective Expression in Carotid
Body Type I Cells of a Single Splice Variant of the Large Conductance Calcium- and Voltage-activated
Potassium Channel Confers Regulation by AMP-activated Protein Kinase' Journal of Biological Chemistry,
vol. 286, no. 14, pp. 11929-11936. DOI: 10.1074/jbc.M110.189779
Digital Object Identifier (DOI):
10.1074/jbc.M110.189779
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Biological Chemistry
Publisher Rights Statement:
Available under Open Access
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Grahame Hardie and A. Mark Evans
Wyatt, Michael J. Shipston, Chris Peers, D.
Widmer, Iain C. M. Rowe, Christopher N. 
Heather McClafferty, Lijun Tian, Helene
Dallas, Oluseye Ogunbayo, Naoko Ikematsu, 
Fiona A. Ross, J. Nicole Rafferty, Mark L.
  
Protein Kinase
Confers Regulation by AMP-activated
Voltage-activated Potassium Channel 
Large Conductance Calcium- and
I Cells of a Single Splice Variant of the 
Selective Expression in Carotid Body Type
Signal Transduction:
doi: 10.1074/jbc.M110.189779 originally published online January 5, 2011
2011, 286:11929-11936.J. Biol. Chem. 
  
 10.1074/jbc.M110.189779Access the most updated version of this article at doi: 
  
.JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/286/14/11929.full.html#ref-list-1
This article cites 36 references, 19 of which can be accessed free at
 by guest on August 6, 2013http://www.jbc.org/Downloaded from 
Selective Expression in Carotid Body Type I Cells of a Single
Splice Variant of the Large Conductance Calcium- and
Voltage-activated Potassium Channel Confers Regulation by
AMP-activated Protein Kinase*
Received for publication, September 29, 2010, and in revised form, December 22, 2010 Published, JBC Papers in Press, January 5, 2011, DOI 10.1074/jbc.M110.189779
Fiona A. Ross‡1, J. Nicole Rafferty§1, Mark L. Dallas¶1, Oluseye Ogunbayo§, Naoko Ikematsu‡, Heather McClafferty§,
Lijun Tian§, HeleneWidmer, Iain C. M. Rowe§, Christopher N. Wyatt**, Michael J. Shipston§, Chris Peers¶,
D. Grahame Hardie‡, and A. Mark Evans§2
From the ‡College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom, the §Centre for Integrative
Physiology, College of Medicine and Veterinary Medicine, Hugh Robson Building, University of Edinburgh, Edinburgh EH8 9XD,
United Kingdom, the ¶School of Medicine, University of Leeds, Leeds LS2 9JT, United Kingdom, Glasgow Caledonian University,
GovanMbeki Health Building, GlasgowG4 0BA, United Kingdom, and the **Department of Neuroscience, Cell Biology, and
Physiology, Wright State University, Boonshoft School of Medicine, Dayton, Ohio 45435
Inhibition of large conductance calcium-activated potassium
(BKCa) channels mediates, in part, oxygen sensing by carotid
body type I cells. However, BKCa channels remain active in cells
that do not serve to monitor oxygen supply. Using a novel, bac-
terially derived AMP-activated protein kinase (AMPK), we
show that AMPK phosphorylates and inhibits BKCa channels in
a splice variant-specific manner. Inclusion of the stress-regu-
lated exon within BKCa channel  subunits increased the stoi-
chiometry of phosphorylation by AMPK when compared with
channels lacking this exon. Surprisingly, however, the increased
phosphorylation conferred by the stress-regulated exon abol-
ished BKCa channel inhibition by AMPK. Point mutation of a
single serine (Ser-657) within this exon reduced channel phos-
phorylation and restored channel inhibition by AMPK. Signifi-
cantly, RT-PCR showed that rat carotid body type I cells express
only the variant ofBKCa that lacks the stress-regulated exon, and
intracellular dialysis of bacterially expressed AMPK markedly
attenuated BKCa currents in these cells. Conditional regulation
of BKCa channel splice variants by AMPK may therefore deter-
mine the response of carotid body type I cells to hypoxia.
Upon exposure to hypoxia, carotid body type I cells depolar-
ize, precipitating voltage-gated Ca2 influx and neurosecre-
tion, which leads to increased sensory afferent discharge to the
brain stem and, ultimately, corrective changes in breathing (1,
2). It is well established that this process is mainly driven by
inhibition of discrete populations of oxygen-sensitive K
channels, and we have recently proposed that hypoxia-re-
sponse coupling in carotid body type I cells is mediated, at least
in part, by the metabolic sensor AMP-activated protein kinase
(AMPK)3 (3, 4).
AMPK exists as heterotrimers comprising catalytic  sub-
units and regulatory  and  subunits (5). It is only active after
phosphorylation of Thr-172 on the  subunit by upstream
kinases, which include the tumor suppressor, LKB1 (6). Activa-
tion occurs in response to cellular stresses that either accelerate
ATP consumption or inhibit ATP production, which increase
the ADP/ATP ratio and, via the action of adenylate kinases,
AMP/ATP. This leads to exchange of AMP for ATP at two sites
on the AMPK  subunit (7), triggering allosteric activation (8)
and inhibition of Thr-172 dephosphorylation (9). AMPK can
also be activated by CaMKK in response to increased cyto-
plasmic Ca2 (10, 11). Once activated, AMPK phosphorylates
downstream targets that activate ATP-generating catabolic
pathways while switching off ATP-consuming processes. Most
targets identified to date are proteins directly involved in
metabolism, cell growth or the cell cycle, or proteins that affect
the expression of genes involved in those processes (5).
Consistent with our proposal that AMPKmediates hypoxia-
response coupling, we recently showed that AMPK activation,
like hypoxia, selectively inhibits oxygen-sensitive K currents
in carotid body type I cells, including the large conductance
Ca2-activated K channel, BKCa (3). We also showed that the
addition of AMPK activators to HEK293 cells stably expressing
the pore-forming BKCa subunits inhibitedmacroscopic chan-
nel currents, and that purified AMPK phosphorylated BKCa 
subunits immunopurified from the cells. However, bothAMPK
(5) and BKCa channels (12) are widely expressed in mammalian
cells, many of which do not function tomonitor oxygen supply.
Functional heterogeneity in BKCa channel properties,
including divergent regulation by the same signaling pathway,
may be conferred through alternate splicing of pre-mRNA
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derived from the single gene encoding the  subunit (Kcnma1).
Thus, previous studies have shown that regulation of BKCa
channels by cyclic AMP-dependent protein kinase (PKA) is
determinedby the subunit splice variant (13, 14) because PKA
has been shown to activate homotetramers containing the
ZERO variant that lacks the “stress-regulated exon” (STREX)
and inhibit homotetramers of variants containing the STREX
exon.As pre-mRNAsplicing is tissue-specific anddevelopmen-
tally regulated (15–17), alternative splicing has also been sug-
gested as an attractive mechanism to explain tissue-specific
regulation of BKCa channels by hypoxia (18).
We therefore considered the possibility that AMPK might
differentially regulate BKCa channel splice variants and in a
manner that may confer tissue-specific regulation of BKCa
channels by hypoxia. To this end,we studiedAMPK-dependent
phosphorylation and regulation of the ZERO and STREX vari-
ants of the BKCa channel  subunits expressed in HEK293 cells
and the regulation by AMPK of endogenous BKCa channels in
carotid body type I cells. Using a novel thiophosphorylated,
phosphatase-resistant formof theAMPKheterotrimer,we pro-
vide evidence that alternate splicing of mRNA encoding the
BKCa  subunits profoundly affects the regulation of the chan-
nel by AMPK. Thus, although both the ZERO and STREX vari-
ants were phosphorylated by AMPK, only K currents carried
by theZEROvariantwere inhibited.Moreover, we demonstrate
that the “AMPK-sensitive” ZERO variant, but not the “AMPK-
insensitive” STREX variant, is expressed in the oxygen-sensi-
tive carotid body type I cells.
EXPERIMENTAL PROCEDURES
Cell Culture and Isolation
HEK293 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% (v/v) fetal bovine
serum and 1% (v/v) antibiotic/antimycotic solution.
Carotid Body Type I Cells
Neonatal rats (10 days) were terminally anesthetized, and
carotid bodies were rapidly removed and placed in ice-cold
phosphate-buffered saline without Ca2 or Mg2 (Sigma).
These were then enzymically dissociated and cultured as
described previously (19).
Cell Transfection
Murine BKCa channel  subunit splice variants (ZERO and
STREX) encoded by the murine Kcnma1 gene (GenBankTM
accession number AF156674) were cloned with a C-terminal
hemagglutinin (HA) tag (14). Site-directedmutagenesis created
an S657Amutationwithin the STREX insert, with themutation
confirmed by DNA sequencing. Cells were transfected with 12
g of DNA using Fugene 6 (Roche Applied Science) for protein
phosphorylation assays or with 1.5 g of DNA using Lipo-
fectamine 2000 (Invitrogen) for electrophysiological assays, fol-
lowing the manufacturer’s instructions.
Purification and Activation of Rat Liver AMPK and Bacterially
Expressed AMPK
A GST fusion of CAMKK was expressed and purified as
described (10). Rat liver AMPK was purified as described pre-
viously (21). A polycistronic plasmid expressing His6-tagged
human AMPK (221 complex, a gift fromAstraZeneca) was
purified using a HIS trap column (GE Healthcare) and eluted
using an imidazole gradient. The fractions containing AMPK
were pooled and dialyzed against 50 mM NaHepes, pH 8.0, 200
mM NaCl, 1 mM dithiothreitol. Adenosine ATPS and other
chemicals were from Sigma-Aldrich.
Bacterially expressed human AMPK was incubated with
CaMKK with ATP or ATPS (200 M) plus MgCl2 (5 mM) at
30 °C. Aliquots were removed at intervals, and the reaction was
stopped by incubation with excess EDTA. Kinase activity was
determined using the SAMS peptide assay as described previ-
ously (22), after the addition of excessMg2. To assess dephos-
phorylation, kinase phosphorylated in the presence of either
ATP or ATPS was incubated with bacterially expressed pro-
tein phosphatase-1 (PP1) sufficient to give complete dephos-
phorylation of the enzyme phosphorylated using ATP in 30
min. Aliquots were removed at intervals, incubated with oka-
daic acid (8 M) to inhibit the phosphatase, and assayed for
AMPK as before. When preparing thiophosphorylated kinase
for electrophysiology studies, AMPK was incubated with
CaMKK for 30 min at 30 °C, CaMKK was removed by
adsorption on GST-Sepharose (GE Healthcare), and the active
AMPK complex was dialyzed against 50 mM NaHepes, pH 8.0,
140 mM KCl.
Phosphorylation Assays
Buffers for lysis and purification were from the MACS
epitope tag protein isolation kit (Miltenyl Biotec). 36–48 h
post-transfection, cells plated on a 10-cm culture dish were
lysed in 400 l of lysis buffer (supplied byMiltenyl Biotec) sup-
plemented with protease inhibitor tablets (Roche Applied Sci-
ence) and 1 mM dithiothreitol. After lysis, cells were left on ice
for 30 min and harvested at 10,000  g/min for 10 min. The
supernatant was removed and incubated with 35 l of HA-
tagged magnetic beads for 30 min at 4 °C. During the incuba-
tion, a Column was placed in the magnetic field of the
MACS separator and equilibrated with 200 l of lysis buffer.
Cell lysate was then applied to the column, followed by 4 200
l of wash buffer 1, 1 100l of wash buffer 2 (buffers supplied
by Miltenyl Biotec), and 4  200 l of wash buffer 3 (50 mM
NaHepes, pH 7.4, 1 mM dithiothreitol). The channel was
dephosphorylated by incubation of PP1 for 30 min at 30 °C,
after which the column was washed with 4  200 l of wash
buffer 3 supplemented with 1 MNaCl, followed by 4 200l of
wash buffer 3. The protein was then incubated with 5 mM
MgCl2, 200M [-32P]ATP, 8M okadaic acid, with or without
bacterially expressed 221 (10 units/ml; activated using
CaMKK andATP as above) orAMPKpurified from rat liver (5
units/ml) in the presence or absence of 200MAMP for 30min
at 30 °C. The column was then washed in 4  200 l of wash
buffer 3 supplemented with 1 M NaCl and 4  200 l of wash
buffer 3. Protein was eluted from the column by incubation
with 20 l of preheated elution buffer (Miltenyl Biotec) for 5
min, followed by elution with 50 l of preheated elution buffer.
Proteins were analyzed on SDS-PAGE using the 4–12% gradi-
ent BisTris system (Invitrogen). Incorporation of phosphoryla-
tion was determined as described previously (3).
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Electrophysiology
Cells were plated onto coverslips and transferred to a record-
ing chamber mounted on the stage of an Olympus CK40 or a
Zeiss Axiovert 200M inverted microscope. All experiments
were carried out at 37  1 °C unless otherwise stated. Whole-
cell patch clamp recordings were obtained in voltage clamp
mode using patch pipettes of 4–7-megaohm resistance.
Recordings from HEK293 cells, transiently transfected with
BKCa splice variants andmutants, were obtained using pipettes
filled with an intracellular solution of the following composi-
tion (pH 7.2): 140 mM KCl, 1 mM BAPTA, 1 mMMgCl2, 0.5 mM
CaCl2, 10 mM HEPES, 1 mM MgATP, 0.3 mM NaGTP. The
calculated free Ca2 concentration for this solutionwas 0.5M.
Cells were bathed in a physiological salt solution of the follow-
ing composition (pH 7.4): 135 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, 10 mM D-glucose, 10 mM HEPES.
Recordings from the type I cells were obtained using pipettes
filled with an intracellular solution of the following composi-
tion (pH 7.2): 10 mM NaCl, 117 mM KCl, 2 mM MgCl2, 11 mM
HEPES, 11 mM EGTA, 1 mM CaCl2, 2 mM Na2ATP. Cells were
continuously superfused (3–5ml/min) with a physiological salt
solution that was constantly bubbled with 95%O2, 5% CO2 and
had the following composition (pH 7.4): 117 mM NaCl, 4.5 mM
KCl, 1mMMgCl2, 23mMNaHCO3, 2.5mMCaCl2, 11mMD-glu-
cose. To identify the contribution of BKCa channels to the total
outward K current, BKCa channels were inhibited by switch-
ing the superfusate to a “high Mg2” perfusate in which 6 mM
MgCl2 and 0.1mMCaCl2 was substituted for 1mMMgCl2 and 2
mM CaCl2 (23).
Series resistance was monitored after breaking into the
whole-cell configuration throughout the duration of experi-
ments. If a significant increase (20%) occurred, the experi-
ment was terminated. Signals were acquired using anAxopatch
200B amplifier (Axon Instruments, Inc.) controlled byClampex
version 9.0 or 10 software via a Digidata 1322A interface (Axon
Instruments, Inc.). Data were filtered at 1 kHz and digitized at 5
kHz. To evoke ionic currents, a step depolarization was applied
from70mV to60 or100mV. Offline analysis was carried
out using Clampfit version 9 or 10 (Axon Instruments, Inc.).
RT-PCR
Whole Carotid Body—Carotid bodies were removed from
P10 rats and placed in RNAlater Tissue Collection: RNA Sta-
bilization Solution (Ambion). RNA was extracted using the
RNeasy microkit (Qiagen) following the manufacturer’s guide-
lines, and concentration was determined using the Nanodrop
1000 spectrophotometer (ThermoScientific). cDNA synthesis
was carried out using theTranscriptorHigh Fidelity cDNAsyn-
thesis kit (RocheApplied Science) following themanufacturer’s
instructions.
For PCR analysis, 5 l of cDNA was used in a 50-l reaction
using GoTaq DNA polymerase (Promega) and the following
primers: BKCa channel  subunit (which spanned the site of
splicing C2 to detect BKCa channel splice variants), forward
(5-gTTTgTgAgCTgTgTTTTgTg) and reverse (5-gTgTTT-
gAgCTCATgATAgTg). To demonstrate that cDNA was, at
least in part, derived from carotid body type I cells in whole
carotid body extracts, primers for tyrosine hydroxylase were
also used for PCR analysis: forward (5-TCCTCCTTg-
TCTCgggCTgTAAAAg) and reverse (5-CTTgggAACCA-
ggggACCTTgTC).
Single Type I Cells—The cellular contents of single, isolated
carotid body type I cells were aspirated into RNase-free boro-
silicate patch pipettes containing 7 l of RNase-free water.
Aspirant was immediately transferred to a microcentrifuge
tube for cDNA synthesis using Sensiscript reverse transcrip-
tase (Qiagen), RNasin ribonuclease inhibitor (Promega) and a
mix of random and poly(dT) primers in a final volume of 20 l
at 37 °C for 1 h. For PCRanalysis, 2–5l of single cell cDNAwas
used in a 20-l reaction using GoTaq DNA polymerase (Pro-
mega) using the same primers as above.
Amplification of single cell cDNA isolated from different
individual cells was run in parallel with multiple negative con-
trols using an initial denaturing step at 94 °C for 5min and then
denaturing at 94 °C for 30 s, annealing at 58 °C for 45 s, and
extension for 60 s at 72 °C using 35–40 cycles with a final 7-min
extension at 72 °C. Negative controls included control cell aspi-
rants, for which no reverse transcriptase was added, and aspi-
ration of extracellular medium and PCR controls. None of the
controls produced any detectable amplicon, ruling out genomic
or other contamination. Amplicons were run on a 1.5% agarose
gel and visualized using SYBRSafeTM (Invitrogen).
Data Analysis
Significance of differences in phosphorylation stoichiometry
with the ZERO, STREX, and S657A mutant STREX variants
was determined by one-way analysis of variance using
GraphPad Prism version 5.0. Effects of AMPK (pharmacologi-
cal activation or application of heterotrimers) were analyzed by
paired or unpaired Student’s t tests, as indicated.
RESULTS
The ZERO and STREX variants of BKCa were transiently
expressed in HEK293 cells, and outward K channel currents
were recorded in the whole-cell configuration under voltage
clamp by applying a voltage step from a holding potential of
70 mV to 100 mV. We then assessed the effect on evoked
current amplitude of extracellular application of two structur-
ally unrelated AMPK activators with different mechanisms of
action: 1) A-769662 (100 M), which activates AMPK by
directly binding to the 1 subunit at a site distinct from the
AMP binding sites (24, 25); 2) 5-aminoimidazole-4-carboxam-
ide riboside (AICAR; 1 mM), a nucleoside that is taken up into
cells and then metabolized to the AMP mimetic, 5-aminoimi-
dazole-4-carboxamide-1-b-D-ribofuranosyl, thus activating
AMPK (8). Fig. 1A shows the effects of A-769662 andAICAR in
cells transfected with the ZERO variant of BKCa. Inhibition of
the current carried by the ZERO variant was clearly observed
after extracellular application of A-769662 in the absence but
not in the presence of 40McompoundC, anAMPKantagonist
that may also inhibit other kinases (26). Consistent with our
earlier study (3), extracellular application of AICAR too inhib-
ited the ZERO variant, an effect we have previously shown to be
blocked by compound C (3). In marked contrast, in cells trans-
fected with the STREX variant (Fig. 1B), the current amplitude
AMPK and BKCa Splice Variants
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remained stable during extracellular application (10 min) of
either A-769662 or AICAR and throughout the current-voltage
range (data not shown). Although both A-769662 and AICAR
have been shown to have AMPK-independent effects, none
have been common to both agents.Moreover, the fact that inhi-
bition of the ZERO variant of BKCa by each AMPK agonist was
abolished by an AMPK antagonist, compound C, provides fur-
ther support for the view that both agents mediate inhibition of
the ZERO variant of the BKCa channel  subunit through
AMPK activation rather than by any other mechanism. That
this is the case gained further support from studies using a
recombinant human 221 heterotrimer (see below).
Given that AMPK activation by A-769662 and AICAR was
without effect on K currents carried by the STREX variant, we
next assessed the impact of the presence of the STREX insert on
phosphorylation of BKCa by AMPK.We first assessed the phos-
phorylation of BKCa channel subunit splice variants byAMPK
purified from rat liver extract (a mixture of the 111 and
211 heterotrimers). The STREX or ZERO variants of BKCa
immunoprecipitated from HEK293 cells were incubated with
rat AMPK and [-32P]ATP in the presence and absence of
AMP. Fig. 2, A and B, shows that rat liver AMPK phosphory-
lated both variants and that this was dependent on the addition
of AMPK and was markedly stimulated by AMP. Fig. 2C shows
immunoprecipitates of ZERO and STREX variants incubated
with [-32P]ATP and bacterially expressed human221 het-
erotrimer that had been activated by incubation with CaMKK
and ATP (note the slightly more rapid migration of the smaller
ZERO variant). The recombinant human AMPK heterotrimer
phosphorylated both variants, but the stoichiometry of phos-
phorylation was significantly higher with the STREX variant,
increasing from 0.96  0.09 mol/mol (n  6) for ZERO to
1.51 0.07 mol/mol for the STREX variant (mean S.D., n
5, p 0.001 by one-way analysis of variance). The STREX insert
contains a serine (Ser-657 in the full sequence, underlined
below) with a surrounding sequence (RSERDCSCMSG) that is
a partial fit to the consensus recognition motif for AMPK (27).
This serine is preceded by the expected arginine residues at
P3 and P6, although bulky hydrophobic residues (rather
than the serine and glycine found at this site) are usually pre-
ferred at positions P5 and P4. Despite this, Fig. 2D shows
that a serine to alanine mutation (S657A) significantly attenu-
ated phosphorylation of the STREX variant, reducing the stoi-
chiometry of phosphorylation from 1.51  0.07 (n  5) to
1.14 0.02 (n 3)mol/mol (p 0.001) (i.e. to a value similar to
that observed with the ZERO variant) (Fig. 2C). Thus, although
the ZERO and STREX variants are both phosphorylated by
AMPK, there may be an additional phosphorylation site in the
STREX variant (possibly Ser-657 within the STREX insert
itself).
We next wished to examine the effect of introducing recom-
binant AMPK by intracellular dialysis on BKCa channel func-
tion in intact cells. Because it was likely that cellular phospha-
tases would dephosphorylate Thr-172, causing inactivation of
the kinase, we purified dephosphorylated and inactive recom-
binant human 221 heterotrimers from bacterial extracts
and activated them using CaMKK and ATPS. This yields
complexes with thiophosphate rather than phosphate at Thr-
FIGURE 1.AMPK-dependent regulation ofwhole-cell currents carried by BKCa splice variants expressed in HEK293 cells. A, bar chart shows the residual
whole-cell K current (I/Imax; mean S.E.) carried by the ZERO splice variant of BKCa after extracellular application of the AMPK agonist A-769662 (100 M) in
the absence and presence of compound C (40M) and after extracellular application of AICAR (1mM). For A-769662, residual current measured 0.68 0.04 of
control (p 0.01) after 6 0.2 min (n 4) in the absence and 0.94 0.06 (n 3) after 10 min in the presence of compound C. For AICAR, residual current
measured 0.72  0.08 of control (p  0.01) after 10  0.5 min (n  4). B, examples of the whole-cell K currents recorded (left panels) and plots of current
magnitude against time (right panels) before and after extracellular application of A-769662 (100M) andAICAR (1mM).C andD, as inA and Bbut for the STREX
splice variant. For A-769662 (i), residual currentmeasured 0.97 0.07 (n 5) after 10min in the absence and 0.96 0.06 (n 3) in the presence of compound
C. For AICAR (ii), residual current measured 1.12 0.15 (n 3) after 10 min.
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172 on the  subunit; it has been previously shown that thio-
phosphate groups are resistant to dephosphorylation (28). Fig.
3A shows that the wild type 221 complexes could be acti-
vated by CaMKK using either ATP or ATPS, although the
amount of activation obtained usingATPSwas about half that
obtainedwithATP.However, although the complex phosphor-
ylated using ATP was rapidly inactivated by incubation with
recombinant PP1, the monothiophosphorylated complex was
completely resistant to PP1 treatment (Fig. 3B). We also con-
firmed the rapid phosphorylation of Thr-172 with ATP and
CaMKK and its subsequent dephosphorylation using PP1 by
Western blotting using a phosphospecific antibody (not
shown), but the thiophosphorylated protein was not be
detected using this antibody.
Fig. 4A shows the effects of thiophosphorylated activeAMPK
and inactive, thiophosphorylated control (D157Amutant, des-
ignated iAMPK) on the ZERO variant of BKCa. Current inhibi-
tion was clearly observed during intracellular dialysis with
active but not inactiveAMPK. By contrast, Fig. 4B shows that in
cells expressing the STREX variant, BKCa current amplitude
remained stable for up to 10 min of intracellular dialysis with
either active or inactive AMPK.
Strikingly, inhibition of BKCa was restored in the STREX var-
iant by a serine to alanine mutation (S657A) within the STREX
insert, so that the results with the S657Amutant were similar to
those obtained with the ZERO variant. Thus, progressive cur-
rent inhibition was observed after extracellular application of
A-769662 (0.68 0.06 after 5 0.2 min; n 6) or intracellular
dialysis of thiophosphorylatedAMPKbut not iAMPK (Fig. 4C).
Therefore, AMPK inhibits the ZERO but not the STREX vari-
ant of the BKCa  subunit, with this switch determined by the
likely phosphorylation of a single conserved serine residue, Ser-
657, within the STREX insert.
We next sought to determine the effect of recombinant
AMPK on BKCa channel currents in acutely isolated carotid
body type I cells. Outward K currents were activated in rat
carotid body type I cells by a voltage step to 60 mV from a
holding potential of 70 mV before and during extracellular
application of A-769662 or intracellular dialysis of the thio-
phosphorylated 221 heterotrimer or the inactive mutant.
In each case, the perfusate was switched to one containing high
Mg2 (6 mM) and low Ca2 (0.1 mM; termed “high Mg2”) to
provide for selective block byMg2/lowCa2 of BKCa channels
in type I cells (23). Thereby, the specific contribution of BKCa
channels to the measured outward current in type I cells was
assessed relative to, for example, the delayed rectifier potassium
current.
As summarized in Fig. 5A, the switch to high Mg2 reduced
outward K currents in type I cells, in agreement with previous
studies (23). Exposure of cells to A-769662 caused progressive
inhibition of currents that peaked after 10min andwas blocked
by the non-selective AMPK antagonist, compound C. Further-
more, subsequent switching to the high Mg2 solution caused
no further inhibition (Fig. 5, C and F). These results are consis-
tentwith our previous finding (3, 29) that pharmacological acti-
vation of AMPK with AICAR leads to inhibition of BKCa chan-
nels without affecting other voltage-gated K currents in type I
carotid body cells. Fig. 5B shows that, when compared with
time-matched controls (containing no heterotrimer), current
inhibition was caused by active AMPK but not iAMPK, reach-
ing a plateau at 8 min (p  0.01; Fig. 5B). As was seen with
application of A-769662, currents observed in cells dialyzed
with the active heterotrimerwere not reduced further following
the switch to perfusate containing high Mg2, indicating that
the heterotrimer had caused selective inhibition of BKCa chan-
nels in type I cells (Fig. 5, D and G). By contrast, dialysis with
inactive AMPKwaswithout significant effect on current ampli-
tudes, and the switch to high Mg2 led to significant current
inhibition, comparable with that seen in cells dialyzed without
FIGURE 2. AMPK-dependent phosphorylation of BKCa splice variants.
Autoradiogram (32P) and Coomassie Blue-stained gel and autoradiogram
demonstrating phosphorylation of the STREX (A) and ZERO (B) splice variants
of BKCa by AMPKpurified from rat liver extract in the presence and absence of
200M AMP. C, autoradiogram and Coomassie Blue-stained gel demonstrat-
ing phosphorylation of the ZERO and STREX variants by human AMPK
(221; 10 units/ml), showing the greater degree of phosphorylation of the
STREX variant. D, autoradiogram and Coomassie Blue-stained gel demon-
strating phosphorylation of the STREX variant and the S657A STREX mutant
by human AMPK (221; 10 units/ml), showing the lower degree of phos-
phorylation of the S657A mutant. Note that for observations analyzed on a
fixed percentage acrylamide protein gel, STREX and ZERO protein migrated
at 137 and 131 kDa, respectively. In contrast, when analyzed on a 4–12%
BisTris precast gel (Invitrogen), the STREX and ZERO proteinsmigratedwith a
smaller apparent mass of 97 and 90 kDa, respectively.
FIGURE3.PhosphorylationanddephosphorylationofAMPKusingATPor
ATPS. A, activation of human AMPK (221) by CaMKK using ATP (open
circles) or ATPS (filled circles). B, activity of AMPK that had been phosphory-
lated using ATP or ATPS (as in A) during subsequent incubationwith PP1.
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added heterotrimers (Fig. 5, B, E, and H). These data provide
both molecular and pharmacological evidence that AMPK
selectively inhibits BKCa channels, rather than other voltage-
gated K currents, in rat carotid body type I cells.
Fig. 6A shows that RT-PCR products from mRNA that was
extracted fromwhole rat carotid bodies (Total CB) correspond-
ing to 1) identified amplicons for both the ZERO and STREX
splice variants of the BKCa  subunit and 2) an as yet unidenti-
fied low molecular weight amplicon (LMA) of the  subunit
(Fig. 6A, left). As a positive control for inclusion of mRNA from
carotid body type I cells, transcripts for tyrosine hydroxylase
were also identified (Fig. 6B, left). Inmarked contrast, end point
RT-PCR (Fig. 6B, right) on single acutely isolated rat carotid
body type I cells identified no STREX amplicon but identified
clear amplicons for the ZERO and the low molecular weight
amplicon of the BKCa  subunit (n 5; Fig. 6A, right) as well as
tyrosine hydroxylase (n  5; Fig. 6B, right). It would appear,
therefore, that theAMPK-sensitive ZEROvariant of the BKCa
subunit is expressed in the oxygen-sensing rat carotid body type
I cells, whereas expression of the AMPK-insensitive STREX
variant is restricted to other cell types within the carotid body.
DISCUSSION
The findings of the present investigation are consistent with
the hypothesis that alternative pre-mRNA splicing of BKCa 
subunits provides a mechanism by which AMPK-dependent
regulation of cell function may be modulated in a cell-specific
manner.
First of all, we provided evidence that AMPK regulates BKCa
channels in a splice variant-specific manner. Thus, two AMPK
agonists with different mechanisms of action, namely AICAR
and A-769662, were shown to inhibit ion channel currents car-
ried by the ZERO but not the STREX variant of the BKCa 
subunit. Moreover, the AMPK antagonist compound C abol-
ished channel regulation by each of these AMPK agonists. It is
highly unlikely, therefore, that AICAR and A-769662 mediate
the same splice variant-specific regulation of BKCa by any
mechanism other than AMPK activation. Nonetheless, off tar-
get effects are still possible. Therefore, we extended our studies
and demonstrated for the first time that intracellular dialysis
from a patch pipette of recombinant human 221 hetero-
trimers, activated by prior thiophosphorylation, also inhibited
ion channel currents carried by the ZERO but not the STREX
variant of the BKCa  subunit. Our data provide, therefore, the
strongest evidence possible that AMPK regulates BKCa channel
function in a splice variant-specific manner.
Nonetheless, subsequent studies on BKCa  subunit phos-
phorylation proved surprising. We showed that AMPK phos-
phorylated both the ZERO and STREX variants of the BKCa 
subunit in a manner stimulated by AMP, despite the fact that
AMPK only inhibited channel currents carried by the ZERO
and not the STREX variant. The fact that channel currents car-
ried by the STREX variant remained functionally unaffected by
AMPK although the  subunit was still phosphorylated was
interesting enough. However, we demonstrated that inclusion
of the STREX insert within the BKCa  subunit increased the
stoichiometry of phosphorylation from 0.96 to 1.5mol/mol (i.e.
that an increase in AMPK-dependent phosphorylation of the 
subunit ablated channel regulation).
FIGURE 4.Regulation by recombinant AMPKheterotrimers ofwhole-cell currents carried by BKCa splice variants expressed inHEK293 cells. Bar charts
show the residual whole-cell K current (I/Imax; mean S.E. (error bars)) carried by the ZERO (A (i)) and STREX (B (i)) splice variants of BKCa and by the S657A
mutant (C (i)) after intracellular dialysis (10 min) of a constitutively active AMPK heterotrimer (AMPK; bacterially derived thiophosphorylated 221) or an
inactive AMPKheterotrimer (iAMPK; bacterially derived kinase-dead221). For the ZERO variant, residual currentmeasured 0.60 0.07 of control (p 0.01)
after 5 0.4 min (n 8) with AMPK and 0.96 0.08 (n 3) after 10 min with iAMPK. For the STREX variant, residual current measured 1.17 0.14 (n 4) of
control with AMPK and 1.15 0.1 (n 3) after 10 min with iAMPK. For the S657Amutant, residual current measured 0.68 0.06 (n 4) of control (p 0.01)
with AMPK and 0.91 0.08 (n 3) with iAMPK after 10min. A–C (ii and iii) show examples of the whole-cell K currents recorded after 0 and 10min (left) and
plots of current magnitude against time following intracellular dialysis of AMPK and iAMPK, respectively, to each of the aforementioned BKCa variants (right).
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Within the STREX insert, a sequence was identified
(RSERDCSCMSG) that is a partial fit to the recognition motif
previously defined for AMPK (27). Mutation of the serine resi-
due within this sequence (S657A) not only reduced the stoichi-
ometry of phosphorylation (from 1.5 to 1.1 mol/mol) but
restored inhibition of the current by AMPK (i.e. this mutation
restored the ZERO phenotype) (Figs. 2 and 4). The simplest
hypothesis to explain these data is that phosphorylation by
AMPK of Ser-657 within the STREX insert ablates the inhibi-
tory effect of phosphorylation by the same enzyme at another
site(s) outside the STREX insert, although other mechanisms
are possible. This has striking parallels with regulation of BKCa
channels by PKA. Phosphorylation of Ser-636 in the STREX
insert by PKA (21 residues upstream of Ser-657) confers chan-
nel inhibition, and this overrides the effect of phosphorylation
by PKA at Ser-927 in the C-terminal region, which results
in channel activation in ZERO variants. Thus, inclusion of an
alternative splice insert, by introducing new phosphorylation
sites, can switch the functional regulation of BKCa channels by
two distinct signaling pathways (AMPK and PKA), each of
which may act in opposition with respect to functional regula-
tion of the ZERO variant.
FIGURE 5. AMPK-dependent regulation of the large conductance Ca2-activated K current in carotid body type I cells. A, bar chart shows the
residual whole-cell K current (I/Imax; mean S.E. (error bars)) recorded under control (1:1000 DMSO) conditions and after a 15-min incubation with the
AMPK agonist A-769662 (100 M) both in the absence and presence of high Mg2 and in the presence of A-769662 and compound C (40 M). Upon
switching to high Mg2, residual outward current (I/Imax; mean  S.E.) measured 0.48  0.04 (p  0.01; n  7) from 0.92  0.03. Residual current
measured 0.53 0.04 (p 0.01; n 7) after 10.28 0.89 min with A-769662 (high Mg2  0.43 0.03; n 6) and 0.81 0.04 (n 7) with A-769662
and compound C. B, bar chart shows the residual whole-cell K current (I/Imax; mean  S.E.) recorded under control conditions and 13 min after
intracellular dialysis of a constitutively active AMPK heterotrimer (AMPK; bacterially derived and thiophosphorylated 221) or inactive AMPK het-
erotrimer (iAMPK; bacterially derived kinase-dead 221) both in the absence and presence of high Mg2. Residual current measured 0.37 0.04 (p
0.01; n 6) after 7.53 0.54 min with AMPK (high Mg2  0.31 0.05; p 0.01; n 6) and 0.79 0.04 (n 6) after 10 min with iAMPK (high Mg2 
0.48 0.04; p 0.01; n 6). The middle panels show example records of whole-cell K current recorded before and after equilibration with A-769662
(C), AMPK (D), and iAMPK (E). The right-hand panels show the time course for inhibition of whole-cell K current during extracellular application of
A-769662 (F) and intracellular dialysis of AMPK (G) and iAMPK (H).
FIGURE 6. Expression of BKCa splice variants in the whole carotid body
and acutely isolated carotid body type I cells. A, gel shows the STREX,
ZERO, and low molecular weight (LMA) BKCa amplicons identified by RT-PCR
from total mRNA extracted from whole carotid bodies (Total CB) (left) and
froma single acutely isolated carotid body type I cell (right). B, paired samples
for A and B showing the tyrosine hydroxylase amplicon (TH). Controls shown
represent aspirants of extracellular medium.
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Therefore, alternative pre-mRNA splicing of BKCa  sub-
units provides amolecular switch that determines channel sen-
sitivity to AMPK, and cell type-specific regulation of splicing
may be utilized to determine functional outcomes. This is sup-
ported by our findings by single cell PCR that rat carotid body
type I cells, the archetypal “oxygen-sensing” cells, express
exclusively the ZERO but not the STREX variant of the BKCa 
subunit (Fig. 6), whereas other cell types within the carotid
body (which do not monitor oxygen supply) also express the
STREX variant. Consistent with the exclusive expression of the
ZERO variant, both theAMPK agonist A-769662 and provision
of active, thiophosphorylated recombinant AMPK by dialysis
via the patch pipette markedly attenuated BKCa channel cur-
rents in carotid body type I cells (Fig. 4).
Our findings may be of more general significance, however,
given that metabolic stresses (e.g. hypoxia and glucose depriva-
tion) could regulate BKCa channels via AMPK in a manner lim-
ited by STREX expression and thereby modulate cell type-spe-
cific outcomes, such as the regulation of vascular tone by
smooth muscle (30, 31) and exocytosis in neuroendocrine cells
(12, 15). That this may be the case is highlighted by the fact that
in adrenal chromaffin cells glucocorticoids may reduce expres-
sion of the STREX variant, whereas the release of adrenal
androgens in response to stress or ACTH may increase its
expression (32, 33). Such plasticity may provide for not only an
adaptive mechanism by which AMPK-dependent regulation of
cellular excitability can be tailored to meet physiological
requirements but one that may also underpin pathophysiolog-
ical outcomes. Thus, aberrant modulation of BKCa channels by
AMPK may be significant in a variety of disorders where BKCa
channel dysfunction has been implicated, such as hypertension
(30, 34), incontinence (35), ataxia (36), and epilepsy (20).
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